An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease

• Main Authors: Sumona Bhattacharya, Raymond K. Cross
• Format: Article
• Language: English
• Published: European Medical Journal 2020-12-01
• Series: European Medical Journal Gastroenterology
• Subjects: biologic therapy; crohn's disease (cd); inflammatory bowel disease (ibd); jak inhibition; ulcerative colitis (uc)
• Online Access: https://www.emjreviews.com/gastroenterology/article/an-overview-of-novel-and-emerging-therapies-for-inflammatory-bowel-disease/

Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease, currently available therapies do not induce or maintain remission in >50% of patients. This underscores the need for additional therapies. In this review, the authors detail the novel therapies vedolizumab, tofacitinib, and ustekinumab and delve into therapies which may come onto the market within the next 10 years, including JAK-1 inhibitors (filgotinib and upadacitinib), IL-23 inhibitors (guselkumab, mirikizumab, and risankizumab), the anti-β4β7 and anti-βEβ7 integrin monoclonal antibody etrolizumab, the sphingosine-1-phosphate subtypes 1 and 5 modulator ozanimod, and mesenchymal stem cells. Further studies are required before these emerging therapies gain approval.